{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:32:10Z","timestamp":1788993130015,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sohag University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A new combination of silodosin and mirabegron has recently obtained approval in the Indian market for addressing the benign prostatic hyperplasia symptoms associated with overactive bladder syndrome. In this study, we present four validated UV-spectrophotometric methods that rely on straightforward mathematical calculations for the quick and simultaneous assay\u00a0of MRB and SLD in commercial tablets and synthetic mixes without the need for prior separation. The suggested methods include dual-wavelength, induced dual-wavelength, ratio difference, and area under the curve. These methods were effectively used to determine SLD and MRB simultaneously in combinations with severe spectrum overlap, showing excellent recoveries free from interference from pharmaceutical excipients. The proposed approaches were assessed and validated following the guidelines set forth by the International Conference for Harmonization (ICH). The methods exhibited linear ranges of 1\u201320\u00a0\u03bcg\u00a0mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    and 1\u201325\u00a0\u03bcg\u00a0mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    for SLD and MRB, respectively. Their environmental friendliness was assessed using the Analytical Greenness Calculator (AGREE) and The Green Analytical Procedure Index (GAPI) tools, demonstrating their supremacy in terms of greenness compared to the reported chromatographic method. There were no appreciable variations in accuracy or precision between the reported chromatographic method and statistical comparisons based on t- and F values. Consequently, these suggested methods are deemed effective in routine analysis of SLD and MRB, serving as cost-effective alternatives in quality control laboratories lacking expensive chromatographic instruments.\n                  <\/jats:p>","DOI":"10.1186\/s13065-025-01411-7","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T22:21:54Z","timestamp":1740954114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Two birds with one stone: sustainable smart spectrophotometric methods for concurrent determination of silodosin and mirabegron: application to dosage forms and greenness assessment"],"prefix":"10.1186","volume":"19","author":[{"given":"Khalid M.","family":"Badr El-Din","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed M.","family":"Derayea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Oraby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Abdelshakour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"3","key":"1411_CR1","first-page":"37","volume":"1","author":"A Shrivastava","year":"2013","unstructured":"Shrivastava A, Aggrawal P. Various analytical methodologies for determination of selective \u03b11A receptor blocker tamsulosin hydrochloride and its combinations in different matrices. World J Anal Chem. 2013;1(3):37\u201348.","journal-title":"World J Anal Chem"},{"key":"1411_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-med-063014-123902","volume":"67","author":"EH Kim","year":"2016","unstructured":"Kim EH, Larson JA, Andriole GL. Management of benign prostatic hyperplasia. Annu Rev Med. 2016;67:137\u201351.","journal-title":"Annu Rev Med"},{"issue":"3","key":"1411_CR3","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/nau.23935","volume":"38","author":"Y Matsukawa","year":"2019","unstructured":"Matsukawa Y, Takai S, Majima T, Funahashi Y, Sassa N, Kato M, et al. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies. Neurourol Urodyn. 2019;38(3):941\u20139.","journal-title":"Neurourol Urodyn"},{"key":"1411_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12894-016-0165-3","volume":"16","author":"T Matsuo","year":"2016","unstructured":"Matsuo T, Miyata Y, Kakoki K, Yuzuriha M, Asai A, Ohba K, et al. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with \u03b11-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. BMC Urol. 2016;16:1\u20138.","journal-title":"BMC Urol"},{"key":"1411_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-023-03880-y","author":"MS Abdel-Kader","year":"2023","unstructured":"Abdel-Kader MS, Sayed AM, Sayed SM, AbdelRazek M. Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones. Int Urol Nephrol. 2023. https:\/\/doi.org\/10.1007\/s11255-023-03880-y.","journal-title":"Int Urol Nephrol"},{"key":"1411_CR6","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S10428","author":"M Rossi","year":"2010","unstructured":"Rossi M, Roumegu\u00e8re T. Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Dev Ther. 2010. https:\/\/doi.org\/10.2147\/DDDT.S10428.","journal-title":"Drug Des Dev Ther"},{"key":"1411_CR7","first-page":"1601","volume":"44","author":"Y Cui","year":"2012","unstructured":"Cui Y, Zong H, Zhang Y. The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis. Int Urol Nephrol. 2012;44:1601\u20139.","journal-title":"Int Urol Nephrol"},{"key":"1411_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-018-0854-2","volume":"36","author":"L Villa","year":"2019","unstructured":"Villa L, Capogrosso P, Capitanio U, Martini A, Briganti A, Salonia A, et al. Silodosin: an update on efficacy, safety and clinical indications in urology. Adv Ther. 2019;36:1\u201318.","journal-title":"Adv Ther"},{"key":"1411_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40265-018-0924-4","volume":"78","author":"ED Deeks","year":"2018","unstructured":"Deeks ED. Mirabegron: a review in overactive bladder syndrome. Drugs. 2018;78:833\u201344.","journal-title":"Drugs"},{"issue":"1","key":"1411_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/nau.22505","volume":"33","author":"CR Chapple","year":"2014","unstructured":"Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17\u201330.","journal-title":"Neurourol Urodyn"},{"key":"1411_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2022.100669","volume":"96","author":"S Joseph","year":"2022","unstructured":"Joseph S, Maria SA, Peedicayil J. Drugs currently undergoing preclinical or clinical trials for the treatment of overactive bladder: a review. Curr Ther Res. 2022;96: 100669. https:\/\/doi.org\/10.1016\/j.curtheres.2022.100669.","journal-title":"Curr Ther Res"},{"issue":"4","key":"1411_CR12","first-page":"150","volume":"5","author":"A Tp","year":"2012","unstructured":"Tp A, Rajasekaran A. Method development and validation for the estimation of sildosin in bulk and pharmaceutical dosage forms using UV-VIS spectrophotometry. Asian J Pharm Clin Res. 2012;5(4):150\u20132.","journal-title":"Asian J Pharm Clin Res"},{"key":"1411_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.saa.2018.04.046","volume":"202","author":"SA Boltia","year":"2018","unstructured":"Boltia SA, Abdelkawy M, Mohammed TA, Mostafa NN. Validated stability-indicating spectrophotometric methods for the determination of Silodosin in the presence of its degradation products. Spectrochim Acta Part A Mol Biomol Spectrosc. 2018;202:131\u201345. https:\/\/doi.org\/10.1016\/j.saa.2018.04.046.","journal-title":"Spectrochim Acta Part A Mol Biomol Spectrosc"},{"key":"1411_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2023.123650","volume":"307","author":"Y Rostom","year":"2024","unstructured":"Rostom Y, Rezk MR, Wadie M, Abdel-Moety EM, Marzouk HM. State-of-the-art mathematically induced filtration approaches for smart spectrophotometric assessment of silodosin and solifenacin mixture in their new challenging formulation: multi-tool greenness and whiteness evaluation. Spectrochim Acta Part A Mol Biomol Spectrosc. 2024;307: 123650. https:\/\/doi.org\/10.1016\/j.saa.2023.123650.","journal-title":"Spectrochim Acta Part A Mol Biomol Spectrosc"},{"key":"1411_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2022.121063","volume":"273","author":"Y Rostom","year":"2022","unstructured":"Rostom Y, Wadie M, Rezk MR, Marzouk HM, Abdel-Moety EM. Fingerprinting and iso-absorptive resolution techniques for the spectrally overlapping Dutasteride and Silodosin mixture: content uniformity testing along with greenness profile assessment. Spectrochim Acta Part A Mol Biomol Spectrosc. 2022;273: 121063. https:\/\/doi.org\/10.1016\/j.saa.2022.121063.","journal-title":"Spectrochim Acta Part A Mol Biomol Spectrosc"},{"issue":"10","key":"1411_CR16","first-page":"5106","volume":"4","author":"SJR PrachiBhamre","year":"2014","unstructured":"PrachiBhamre SJR. Spectrofluorimetric method for the determination of silodosin in bulk and pharmaceutical dosage form. Indo Am J Pharm Res. 2014;4(10):5106\u201310.","journal-title":"Indo Am J Pharm Res"},{"key":"1411_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10895-016-1973-2","volume":"27","author":"MA Omar","year":"2017","unstructured":"Omar MA, Mohamed AMI, Derayea SM, Hammad MA, Mohamed AA. Selective spectrofluorimetric method with enhanced sensitivity for determination of silodosine in dosage form and human plasma. Application to stability studies and content uniformity testing. J Fluoresc. 2017;27:473\u201382.","journal-title":"J Fluoresc"},{"key":"1411_CR18","first-page":"10","volume":"1","author":"PS Sayana","year":"2012","unstructured":"Sayana PS, Iyer RS, Shibi A, Harischandran S. Development and validation of HPTLC method for quantification of silodosin in bulk and pharmaceutical dosage form. Pharma Innov. 2012;1:10.","journal-title":"Pharma Innov"},{"key":"1411_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.scp.2023.101095","volume":"33","author":"M Wadie","year":"2023","unstructured":"Wadie M, Abdel-Moety EM, Rezk MR, Marzouk HM. Sustainable and smart HPTLC determination of silodosin and solifenacin using a constructed two illumination source chamber with a smartphone camera as a detector: comparative study with conventional densitometric scanner. Sustain Chem Pharm. 2023;33: 101095. https:\/\/doi.org\/10.1016\/j.scp.2023.101095.","journal-title":"Sustain Chem Pharm"},{"key":"1411_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.202300178","author":"S Lodha","year":"2023","unstructured":"Lodha S, Pillai A, Kalyankar G, Dedhiya P, Joshi S, Shah S, et al. High-performance thin layer chromatographic method development and validation for simultaneous estimation of solifenacin succinate and silodosin using quality by design approach and greenness assessment. Sep Sci Plus. 2023. https:\/\/doi.org\/10.1002\/sscp.202300178.","journal-title":"Sep Sci Plus"},{"issue":"29","key":"1411_CR21","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1016\/j.jchromb.2009.08.025","volume":"877","author":"X Zhao","year":"2009","unstructured":"Zhao X, Liu Y, Xu J, Zhang D, Zhou Y, Gu J, et al. Determination of silodosin in human plasma by liquid chromatography\u2013tandem mass spectrometry. J Chromatogr B. 2009;877(29):3724\u20138. https:\/\/doi.org\/10.1016\/j.jchromb.2009.08.025.","journal-title":"J Chromatogr B"},{"issue":"2","key":"1411_CR22","doi-asserted-by":"publisher","first-page":"2200117","DOI":"10.1002\/sscp.202200117","volume":"6","author":"S Dhiman","year":"2023","unstructured":"Dhiman S, Kurmi BD, Asati V. Analytical reversed-phase high-performance liquid chromatography method development for silodosin and solifenacin in bulk and marketed formulation using analytical quality by design approach. Sep Sci Plus. 2023;6(2):2200117.","journal-title":"Sep Sci Plus"},{"issue":"3","key":"1411_CR23","first-page":"993","volume":"14","author":"ME Yaman","year":"2021","unstructured":"Yaman ME, Akman T\u00c7. Optimization of HPLC-FLD conditions using analytical quality by design approach for quantification of silodosin in pharmaceutical dosage form. Erzincan Univ J Sci Technol. 2021;14(3):993\u20131005.","journal-title":"Erzincan Univ J Sci Technol"},{"issue":"6","key":"1411_CR24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/rcm.7821","volume":"31","author":"S Pandeti","year":"2017","unstructured":"Pandeti S, Narender T, Prabhakar S, Reddy TJ. Characterization of degradation products of silodosin under stress conditions by liquid chromatography\/fourier transform mass spectrometry. Rapid Commun Mass Spectrom. 2017;31(6):572\u201382.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"1","key":"1411_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1556\/1326.2016.00150","volume":"30","author":"QH Yin","year":"2018","unstructured":"Yin QH, Zhu YQ, Yang YL. Determination of silodosin in biological samples using UPLC\u2013MS\/MS combined with magnetic carboxylated multiwalled carbon nanotubes. Acta Chromatogr. 2018;30(1):47\u201353.","journal-title":"Acta Chromatogr"},{"issue":"5","key":"1411_CR26","first-page":"311","volume":"59","author":"B Toker","year":"2014","unstructured":"Toker B, Era E, Erka N. Development of voltammetric techniques for the determination of silodosin in pharmaceutical formulation at glassy carbon electrode. Rev Roum Chim. 2014;59(5):311\u20136.","journal-title":"Rev Roum Chim"},{"key":"1411_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.electacta.2015.01.020","volume":"157","author":"E Er","year":"2015","unstructured":"Er E, \u00c7elikkan H, Erk N, Aksu ML. A new generation electrochemical sensor based on graphene nanosheets\/gold nanoparticles\/nafion nanocomposite for determination of Silodosin. Electrochim Acta. 2015;157:252\u20137. https:\/\/doi.org\/10.1016\/j.electacta.2015.01.020.","journal-title":"Electrochim Acta"},{"issue":"11","key":"1411_CR28","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/elan.202200085","volume":"34","author":"AS Abo Elalaa","year":"2022","unstructured":"Abo Elalaa AS, Abdel-Hamied Abdel-Tawab M, Abdel Ghani NT, El Nashar RM. Computational design and application of molecularly imprinted\/MWCNT based electrochemical sensor for the determination of silodosin. Electroanalysis. 2022;34(11):1802\u201320.","journal-title":"Electroanalysis"},{"key":"1411_CR29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s10812-021-01126-2","volume":"87","author":"KP Roopa","year":"2021","unstructured":"Roopa KP, Basavaiah K, Shankara BS, Mahesh B. Development and validation of spectrophotometric methods for the assay of Mirabegron in bulk and pharmaceutical formulations. J Appl Spectrosc. 2021;87:1171\u20138.","journal-title":"J Appl Spectrosc"},{"issue":"4","key":"1411_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.33974\/ijrpst.v1i4.207","volume":"1","author":"BK Suresh","year":"2020","unstructured":"Suresh BK, Anusha N, Sravani AB. Analytical method development and validation for the estimation of Mirabegron in pure and its solid dosage form by UV spectrophotometric method. Int J Res Pharm Sci Technol. 2020;1(4):146\u201350.","journal-title":"Int J Res Pharm Sci Technol"},{"key":"1411_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.scp.2023.100976","volume":"32","author":"RA Sayed","year":"2023","unstructured":"Sayed RA, Mohamed AR, Shalaby A, Ibrahim H. Earth-friendly-assessed UV-spectrophotometric approaches for concurrent determination of Mirabegron and Solifenacin succinate in different matrices. Sustain Chem Pharm. 2023;32: 100976.","journal-title":"Sustain Chem Pharm"},{"key":"1411_CR32","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1134\/S1061934818090095","volume":"73","author":"RK Papanna","year":"2018","unstructured":"Papanna RK, Gowda JBK, Nagaraja P. An experimental design approach for optimization of spectrophotometric estimation of mirabegron in bulk and pharmaceutical formulations. J Anal Chem. 2018;73:884\u201393.","journal-title":"J Anal Chem"},{"key":"1411_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2020.118509","volume":"239","author":"S Morshedy","year":"2020","unstructured":"Morshedy S, Omran G, Abdullatef OA, Omar M, Talaat W. Validated spectrofluorimetric method for determination of mirabegron by utilizing its quenching effect on acetoxymercuric fluorescein reagent. Spectrochim Acta Part A Mol Biomol Spectrosc. 2020;239: 118509.","journal-title":"Spectrochim Acta Part A Mol Biomol Spectrosc"},{"key":"1411_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2023.122473","volume":"293","author":"NA Farid","year":"2023","unstructured":"Farid NA, Youssef NF, Abdellatef HE, Sharaf YA. Spectrofluorimetric methods for the determination of mirabegron by quenching tyrosine and L-tryptophan fluorophores: Recognition of quenching mechanism by stern volmer relationship, evaluation of binding constants and binding sites. Spectrochim Acta Part A Mol Biomol Spectrosc. 2023;293: 122473.","journal-title":"Spectrochim Acta Part A Mol Biomol Spectrosc"},{"key":"1411_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2024.124515","author":"SM Derayea","year":"2024","unstructured":"Derayea SM, Ahmed AS, Abdelshakour MA, Oraby M, El-Din KMB. Diaryl pyrrolone fluorescent probing strategy for Mirabegron determination through condensation with ninhydrin and phenylacetaldehyde: application to dosage forms, human urine and plasma. Spectrochim Acta Part A Mol Biomol Spectrosc. 2024. https:\/\/doi.org\/10.1016\/j.saa.2024.124515.","journal-title":"Spectrochim Acta Part A Mol Biomol Spectrosc"},{"issue":"4","key":"1411_CR36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1080\/22297928.2021.1938216","volume":"11","author":"PN Yadav","year":"2021","unstructured":"Yadav PN, Chhalotiya UK, Kachhiya HM, Patel KM, Shah DA. Quantification of \u03b2-adrenergic receptor agonist drug Mirabegron in presence of degradants by high performance thin layer chromatography. Anal Chem Lett. 2021;11(4):512\u201322.","journal-title":"Anal Chem Lett"},{"key":"1411_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10337-016-3210-1","volume":"80","author":"AM Yehia","year":"2017","unstructured":"Yehia AM, Sami I, Riad SaM, El-Saharty YS. Comparison of two stability-indicating chromatographic methods for the determination of Mirabegron in presence of its degradation product. Chromatographia. 2017;80:99\u2013107.","journal-title":"Chromatographia"},{"issue":"10","key":"1411_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5449","volume":"36","author":"N Konduru","year":"2022","unstructured":"Konduru N, Kowtharapu LP, Gundla R. Unique liquid chromatography technique for the determination of mirabegron in the presence of polymers; robustness by design expert in the light of quality by design. Biomed Chromatogr. 2022;36(10): e5449.","journal-title":"Biomed Chromatogr"},{"issue":"11","key":"1411_CR39","first-page":"6880","volume":"6","author":"R Spandana","year":"2016","unstructured":"Spandana R, Rao RN, Reddy LSS. Analytical method development and validation for the estimation of mirabegron in bulk and pharmaceutical dosage form by RP-HPLC. IAJPR. 2016;6(11):6880\u20137.","journal-title":"IAJPR"},{"issue":"08","key":"1411_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.47191\/ijpbms\/v2-i8-01","volume":"2","author":"J Patel","year":"2022","unstructured":"Patel J, Patel G, Meshram D. Development and validation of UV and RP-HPLC methods for simultaneous estimation of Mirabegron and Solifenacin succinate in their pharmaceutical dosage form. Int J Pharm Bio Med Sci. 2022;2(08):223\u201332.","journal-title":"Int J Pharm Bio Med Sci"},{"key":"1411_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1590\/1806-9282.65.2.141","volume":"65","author":"L Chen","year":"2019","unstructured":"Chen L, Zhang Y. Determination of Mirabegron in rat plasma by UPLC\u2013MS\/MS after oral and intravenous administration. Rev Assoc Med Bras. 2019;65:141\u20138.","journal-title":"Rev Assoc Med Bras"},{"key":"1411_CR42","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jchromb.2012.01.018","volume":"887","author":"R Van Teijlingen","year":"2012","unstructured":"Van Teijlingen R, Meijer J, Takusagawa S, Van Gelderen M, Van Den Beld C, Usui T. Development and validation of LC\u2013MS\/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. J Chromatogr B. 2012;887:102\u201311.","journal-title":"J Chromatogr B"},{"issue":"39","key":"1411_CR43","doi-asserted-by":"publisher","first-page":"31024","DOI":"10.1039\/C5RA01711D","volume":"5","author":"PD Kalariya","year":"2015","unstructured":"Kalariya PD, Sharma M, Garg P, Thota JR, Ragampeta S, Talluri MVNK. Characterization of stress degradation products of mirabegron using UPLC-QTOF-MS\/MS and in silico toxicity predictions of its degradation products. RSC Adv. 2015;5(39):31024\u201338.","journal-title":"RSC Adv"},{"issue":"4","key":"1411_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202103852","volume":"7","author":"MM Abou El-Alamin","year":"2022","unstructured":"Abou El-Alamin MM, Mohamed DA, Toubar SS. Electrochemical determination of Mirabegron at silica modified carbon paste in micellar medium: sensitive application with drug product and spiked plasma. ChemistrySelect. 2022;7(4): e202103852.","journal-title":"ChemistrySelect"},{"key":"1411_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2023.12.013","author":"S Mishra","year":"2023","unstructured":"Mishra S, Chauhan A. Development and validation of stability indicating RP-HPLC method for simultaneous estimation of silodosin and Mirabegron in synthetic mixture. Ann Pharm Fr. 2023. https:\/\/doi.org\/10.1016\/j.pharma.2023.12.013.","journal-title":"Ann Pharm Fr"},{"issue":"12","key":"1411_CR46","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/bmc.2980","volume":"27","author":"MG Hassan","year":"2013","unstructured":"Hassan MG, Ikeda R, Wada M, Kuroda N, Abdel-Wadood HM, Mohamed HA, et al. Interaction study of acetylcholinestrase inhibitors on pharmacokinetics of memantine in rat plasma by HPLC-fluorescence method. Biomed Chromatogr. 2013;27(12):1685\u20139.","journal-title":"Biomed Chromatogr"},{"issue":"2","key":"1411_CR47","first-page":"167","volume":"65","author":"K Badr El-Din","year":"2022","unstructured":"Badr El-Din K, Ahmed A, Khorshed A, Derayea S, Oraby M. Smart spectrophotometric methods based on feasible mathematical processing and classical Chemometry for the simultaneous assay of Alcaftadine and ketorolac in their recently approved pharmaceutical formulation. Egypt J Chem. 2022;65(2):167\u201374.","journal-title":"Egypt J Chem"},{"issue":"1","key":"1411_CR48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13065-023-00984-5","volume":"17","author":"SM Derayea","year":"2023","unstructured":"Derayea SM, Abu-Hassan AA, Hamad AA, Eltoukhi WE, Hamad AE, Mohammed BS. Mathematical processing of absorption as green smart spectrophotometric methods for concurrent assay of hepatitis C antiviral drugs, Sofosbuvir and Simeprevir: application to combined pharmaceutical dosage forms and evaluation of the method greenness. BMC Chem. 2023;17(1):75.","journal-title":"BMC Chem"},{"issue":"1","key":"1411_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-022-00860-8","volume":"16","author":"H Ibrahim","year":"2022","unstructured":"Ibrahim H, El-Abassy OM, Abdellatef HE, Hendawy HAM, El-Sayed HM. Simultaneous analysis of two drugs used as supportive treatment for COVID-19: comparative statistical studies and analytical ecological appraisal. BMC Chem. 2022;16(1):1\u201315.","journal-title":"BMC Chem"},{"issue":"5","key":"1411_CR50","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/jaoacint\/qsac049","volume":"105","author":"AH Abdelazim","year":"2022","unstructured":"Abdelazim AH, Ramzy S, Abdel-Monem AH, Almrasy AA, Abdel-Fattah A, Shahin M. Quantitative spectrophotometric analysis of celecoxib and tramadol in their multimodal analgesia combination tablets. J AOAC Int. 2022;105(5):1479\u201383.","journal-title":"J AOAC Int"},{"key":"1411_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202300216","author":"MA Abdelshakour","year":"2023","unstructured":"Abdelshakour MA, Eissa MS, Attala K, Elsonbaty A, Abdel Salam RA, Hadad GM, et al. Greenness-by-design approach for developing novel UV spectrophotometric methodologies resolving a quaternary overlapping mixture. Arch Pharm. 2023. https:\/\/doi.org\/10.1002\/ardp.202300216.","journal-title":"Arch Pharm"},{"key":"1411_CR52","unstructured":"ICH: Q2 (R1): validation of analytical procedures: text and methodology. International Conference on Harmonization: Geneva. 2005."},{"key":"1411_CR53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"J P\u0142otka-Wasylka","year":"2018","unstructured":"P\u0142otka-Wasylka J. A new tool for the evaluation of the analytical procedure: green analytical procedure index. Talanta. 2018;181:204\u20139.","journal-title":"Talanta"},{"issue":"14","key":"1411_CR54","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira F, Wojnowski W, Tobiszewski M. AGREE\u2014analytical GREEnness metric approach and software. Anal Chem. 2020;92(14):10076\u201382.","journal-title":"Anal Chem"},{"issue":"6","key":"1411_CR55","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/03639045.2021.1908341","volume":"47","author":"RA Sayed","year":"2021","unstructured":"Sayed RA, Mohamed AR, Hassan WS, Elmasry MS. Comparative study of novel green UV-spectrophotometric platforms for simultaneous rapid analysis of flumethasone pivalate and clioquinol in their combined formulation. Drug Dev Ind Pharm. 2021;47(6):867\u201377.","journal-title":"Drug Dev Ind Pharm"},{"key":"1411_CR56","volume-title":"Green analytical chemistry: theory and practice","author":"M De La Guardia","year":"2010","unstructured":"De La Guardia M, Armenta S. Green analytical chemistry: theory and practice. Amsterdam: Elsevier; 2010."},{"key":"1411_CR57","doi-asserted-by":"publisher","first-page":"106329","DOI":"10.1016\/j.microc.2021.106329","volume":"167","author":"M Oraby","year":"2021","unstructured":"Oraby M, Ahmed AS, Abdel-Lateef MA, Mostafa MAH, Hassan AI. Employ FTIR spectroscopic method for determination of certain multiple sclerosis medications in plasma and pharmaceutical formulations. Microchem J. 2021;167:106329\u201335. https:\/\/doi.org\/10.1016\/j.microc.2021.106329.","journal-title":"Microchem J"},{"issue":"1","key":"1411_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-024-01116-3","volume":"18","author":"SM Derayea","year":"2024","unstructured":"Derayea SM, Badr El-Din KM, Ahmed AS, Khorshed AA, Oraby M. Development of a green synchronous spectrofluorimetric technique for simultaneous determination of Montelukast sodium and Bilastine in pharmaceutical formulations. BMC Chem. 2024;18(1):1\u201313.","journal-title":"BMC Chem"},{"issue":"1","key":"1411_CR59","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13065-024-01137-y","volume":"18","author":"SM Derayea","year":"2024","unstructured":"Derayea SM, Badr El-din KM, Ahmed AS, Khorshed AA, Oraby M. Determination of antihistaminic drugs alcaftadine and olopatadine hydrochloride via ion-pairing with eosin Y as a spectrofluorimetric and spectrophotometric probe: application to dosage forms. BMC Chem. 2024;18(1):40.","journal-title":"BMC Chem"},{"key":"1411_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2024.123986","volume":"311","author":"SM Derayea","year":"2024","unstructured":"Derayea SM, El-Din KMB, Ahmed AS, Abdelshakour MA, Oraby M. An eco-friendly one-pot spectrofluorimetric approach for the facile determination of overactive bladder drug, tolterodine: Application to dosage forms and biological fluids. Spectrochim Acta Part A Mol Biomol Spectrosc. 2024;311: 123986.","journal-title":"Spectrochim Acta Part A Mol Biomol Spectrosc"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01411-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-025-01411-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01411-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T10:12:36Z","timestamp":1740996756000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-025-01411-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1411"],"URL":"https:\/\/doi.org\/10.1186\/s13065-025-01411-7","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate:"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"56"}}